ROCKVILLE, Md., Feb. 9, 2010 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) (the “Company”) announced today that it has commenced mailing its definitive proxy statement to stockholders for approval of the exclusive option and license agreement (“the NicVAX agreement”) between the Company and GlaxoSmithKline Biologicals S.A. dated as of November 13, 2009 and the transactions contemplated thereby. The Company has scheduled a special meeting of stockholders for Tuesday, March 2, 2010 at 10:00 a.m. (EST) at the Bethesda Marriott, 5151 Pooks Hill Road in Bethesda, Maryland, to consider and vote on the NicVAX agreement and the transactions contemplated thereby. Stockholders of record as of the close of business on January 25, 2010 will be entitled to vote at the special meeting.
